# Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

> **NCT04381494** · PHASE4 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- Unresectable Stage III NSCLC

## Interventions

- **DEVICE:** Multiparametric Mobile Technology

## Key facts

- **NCT ID:** NCT04381494
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-27
- **Primary completion:** 2022-01-27
- **Final completion:** 2022-01-27
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Study was not terminated for any safety concerns; it was stopped early due to inability to enroll patients in a timely manner and retain patients on study for the entire duration
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04381494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04381494, "Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04381494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*